Leslie Meltzer's most recent trade in Apellis Pharmaceuticals Inc was a trade of 92,592 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Aug. 26, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Apellis Pharmaceuticals Inc | Leslie Meltzer | Chief Research and Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Aug 2025 | 92,592 | 92,592 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Leslie Meltzer | Chief Research and Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Aug 2025 | 61,804 | 61,804 (0%) | 0% | 0 | Common Stock |